flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 FLOWing with the — NephJC Semaglutide in patients with overweight
Description
Not the right tool
Dehydration is a common but often preventable side effect reported by patients taking semaglutide and other GLP-1 receptor agonists
Its important to remember that the initial dose, often 2.5mg, is primarily designed to help your body adjust to the medication
It is not known if Wegovy injection is safe and effective: to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 years to help children under 12 years of age lose weight and keep the weight off This site is intended for US patients only
Patients will see the most progressive weight loss a few months into treatment
Journal of Endocrinology
